TY - JOUR T1 - First American Cancer Patient to Receive Dicycloplatin (DCP) Chemotherapy Achieves Remission After Seven Weeks of DCP Capsules – A Case Report JF - Anticancer Research JO - Anticancer Res SP - 1339 LP - 1344 DO - 10.21873/anticanres.15602 VL - 42 IS - 3 AU - MOHAMAD W. SALKINI AU - XUQING YANG AU - FAYYAZ HAIDER HASHMI AU - STANLEY J. KANDZARI AU - THOMAS HOGAN AU - CHAD MORLEY AU - DAVID ZEKAN AU - ZACHARY WERNER AU - DORIAN J. WILLIAMS AU - YI GUO AU - THOMAS LEWIS MATTHEW AU - MICHAEL SPANGLER AU - JING JIE YU Y1 - 2022/03/01 UR - http://ar.iiarjournals.org/content/42/3/1339.abstract N2 - Background: The majority of bladder cancer patients experience recurrence. Cisplatin is the standard chemotherapy for muscle-invasive bladder cancer though adverse effects are often severe. Case Report: Intravenous (IV) dicycloplatin (DCP) sustained remission in an American bladder cancer patient for five years. A recurrent mass was observed in July 2021. The patient received DCP capsules for seven weeks with no significant side-effects. Complete blood count with differential and a basic metabolic panel showed no adverse effects of DCP capsules on the bone marrow, liver or renal parameters. Cystoscopy after oral DCP found no evident bladder tumors; cytology was negative for high-grade urothelial carcinoma. Conclusion: In this patient, DCP-capsules appeared to be as effective as DCP-IV for achieving bladder cancer remission. Both forms of DCP chemotherapy are convenient, active against several cancer types, with decreased adverse effects compared to cisplatin. Both have been available for treating cancer patients in China. A USA clinical trial of DCP in bladder and other cancers appears warranted. ER -